Authored by: Huang Jianwen , Zhang Yu and Liang Xiaoyan
On June 27, 2022, the Department of Comprehensive Affairs of the National Medical Products Administration (the “NMPA”) issued the Notice of the Department of Comprehensive Affairs of the National Medical Products Administration on Further Strengthening Services Provided to Foreign Invested Enterprises (the “Notice”). The Notice proposes to enhance services provided to foreign invested enterprises (the “FIEs”) in eight aspects, including improving assistance provided to enterprises, innovating regulatory methods and means, accelerating evaluation and approval process of innovative and urgently needed products, promoting implementation of drug patent linkage system, actively promoting international rules internalization, comprehensively strengthening drug regulatory capacity construction, smoothing regular and open channels for enterprises to voice their demands, and further strengthening drug safety regulations.